Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo macitentan Clear all
Completed Phase 2 Interventional Results available

Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction

NCT02070991
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Macitentan, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
Louisville, Kentucky • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Sep 1, 2026, 11:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

NCT03153111
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Macitentan, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 1, 2026, 11:56 PM EDT
Active, not recruiting Phase 3 Interventional

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

NCT04273945
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
43
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 1, 2026, 11:56 PM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

NCT02558231
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan, Tadalafil, Selexipag
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
20
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 1, 2026, 11:56 PM EDT
Completed Phase 3 Interventional Results available

Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients

NCT01474109
View directory record Official record
Conditions
Systemic Sclerosis, Ulcers
Interventions
macitentan 3mg, macitentan 10mg, placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • Aventura, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Sep 1, 2026, 11:56 PM EDT
Withdrawn Phase 3 Interventional

Macitentan to Prevent PRVO

NCT05946811
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Macitentan 10mg
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Sep 1, 2026, 11:56 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)

NCT01824290
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Tadalafil, Placebo, ERA as specific PAH treatment
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
7
States / cities
Atlanta, Georgia • Detroit, Michigan • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 1, 2026, 11:56 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

NCT01743001
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan 10 mg, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 1, 2026, 11:56 PM EDT
Completed Phase 3 Interventional Results available

Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension

NCT00660179
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
macitentan (ACT-064992), placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
33
States / cities
Birmingham, Alabama • Pheonix, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Sep 1, 2026, 11:56 PM EDT
Completed Phase 2 Interventional Results available

Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study

NCT00903331
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
ACT-064992 (macitentan), Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2014 · Synced Sep 1, 2026, 11:56 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

NCT04271475
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
Macitentan, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 80 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
24
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 1, 2026, 11:56 PM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation

NCT02554903
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Macitentan 10mg, Placebo sugar pill
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
50
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 1, 2026, 11:56 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT03904693
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Interventions
FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg, Placebo FDC, Placebo macitentan, Placebo tadalafil
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
26
States / cities
Fullerton, California • Los Angeles, California • Atlanta, Georgia + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 1, 2026, 11:56 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects

NCT03153137
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Macitentan 10 mg, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 1, 2026, 11:56 PM EDT
Withdrawn Phase 4 Interventional

Macitentan in the Treatment of Organ Rejection After Lung Transplantation

NCT02893176
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
macitentan, placebo (for macitentan)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 1, 2026, 11:56 PM EDT
Completed Phase 4 Interventional Results available

PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial

NCT02382016
View directory record Official record
Conditions
Portopulmonary Hypertension
Interventions
Macitentan, Placebo
Drug · Other
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
29
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 1, 2026, 11:56 PM EDT